These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 31374469)
1. Efficacy and impact on cognitive functions and quality of life of perampanel as first add-on therapy in patients with epilepsy: A retrospective study. Rea R; Traini E; Renna R; Pagliuca F; Pezzella M; Pagliuca M Epilepsy Behav; 2019 Sep; 98(Pt A):139-144. PubMed ID: 31374469 [TBL] [Abstract][Full Text] [Related]
2. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316 [TBL] [Abstract][Full Text] [Related]
3. One-Year Retention Study of Adjunctive Perampanel Treatment in Epilepsy Patients. Kim DW; Oh J Clin Neuropharmacol; 2018; 41(1):10-13. PubMed ID: 29194110 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs. Yamamoto Y; Usui N; Nishida T; Takahashi Y; Imai K; Kagawa Y; Inoue Y Ther Drug Monit; 2017 Aug; 39(4):446-449. PubMed ID: 28703720 [TBL] [Abstract][Full Text] [Related]
5. [Perampanel as a therapy option in patients with epilepsy]. Hintz M; Nawratil S; Schulze-Bonhage A Nervenarzt; 2016 Aug; 87(8):870-8. PubMed ID: 27271515 [TBL] [Abstract][Full Text] [Related]
6. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Patsalos PN Epilepsia; 2015 Jan; 56(1):12-27. PubMed ID: 25495693 [TBL] [Abstract][Full Text] [Related]
7. The discovery and development of perampanel for the treatment of epilepsy. Hanada T Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052 [TBL] [Abstract][Full Text] [Related]
8. Perampanel: Does it have broad-spectrum potential? Potschka H; Trinka E Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584 [TBL] [Abstract][Full Text] [Related]
9. A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment. Huber B; Schmid G Epilepsy Behav; 2017 Jan; 66():74-79. PubMed ID: 28038390 [TBL] [Abstract][Full Text] [Related]
10. Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy. Russmann V; Salvamoser JD; Rettenbeck ML; Komori T; Potschka H Epilepsia; 2016 Apr; 57(4):638-47. PubMed ID: 26854031 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis. Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783 [TBL] [Abstract][Full Text] [Related]
12. The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia. Brito da Silva A; Pennifold J; Henley B; Chatterjee K; Bateman D; Whittaker RW; Joshi A; Kumar H; Nicholson C; Baker MR; Greenhill SD; Walsh R; Seri S; Jones RSG; Woodhall GL; Cunningham MO Epilepsia Open; 2022 Sep; 7(3):488-495. PubMed ID: 34653311 [TBL] [Abstract][Full Text] [Related]
13. Development of perampanel in epilepsy. Satlin A; Kramer LD; Laurenza A Acta Neurol Scand Suppl; 2013; (197):3-8. PubMed ID: 23480150 [TBL] [Abstract][Full Text] [Related]
14. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability. Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234 [TBL] [Abstract][Full Text] [Related]
15. Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. Maschio M; Pauletto G; Zarabla A; Maialetti A; Ius T; Villani V; Fabi A; Koudriavtseva T; Giannarelli D Int J Neurosci; 2019 Jun; 129(6):593-597. PubMed ID: 30507318 [TBL] [Abstract][Full Text] [Related]
16. Introduction: Perampanel--new mode of action and new option for patients with epilepsy. Steinhoff BJ Epilepsia; 2014 Jan; 55 Suppl 1():1-2. PubMed ID: 24400689 [TBL] [Abstract][Full Text] [Related]
17. A Liquid Chromatography-Mass Spectrometry Assay for Determination of Perampanel and Concomitant Antiepileptic Drugs in the Plasma of Patients With Epilepsy Compared With a Fluorescent HPLC Assay. de Grazia U; DʼUrso A; Ranzato F; De Riva V; Contarato G; Billo G; Perini F; Galloni E Ther Drug Monit; 2018 Aug; 40(4):477-485. PubMed ID: 29746395 [TBL] [Abstract][Full Text] [Related]
18. Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience. Juhl S; Rubboli G Acta Neurol Scand; 2016 Nov; 134(5):374-377. PubMed ID: 26763771 [TBL] [Abstract][Full Text] [Related]
19. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy. Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941 [TBL] [Abstract][Full Text] [Related]
20. Perampanel in brain tumor-related epilepsy: Observational pilot study. Maschio M; Zarabla A; Maialetti A; Giannarelli D; Koudriavtseva T; Villani V; Zannino S Brain Behav; 2020 Jun; 10(6):e01612. PubMed ID: 32285623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]